(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Cystic Fibrosis Bronchiectasis pipeline constitutes 15+ key companies continuously working towards developing 15+ Non-Cystic Fibrosis Bronchiectasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Non-Cystic Fibrosis Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Cystic Fibrosis Bronchiectasis Market.
Some of the key takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Non-Cystic Fibrosis Bronchiectasis treatment therapies with a considerable amount of success over the years.
-
Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others, are developing therapies for the Non-Cystic Fibrosis Bronchiectasis treatment
-
Emerging Non-Cystic Fibrosis Bronchiectasis therapies in the different phases of clinical trials are- NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others are expected to have a significant impact on the Non-Cystic Fibrosis Bronchiectasis market in the coming years.
-
In August 2025, The FDA has approved brensocatib (Brinsupri; Insmed) for treating non–cystic fibrosis bronchiectasis, making it the first therapy approved for this patient population and the first dipeptidyl peptidase 1 (DPP1) inhibitor authorized for a neutrophil-mediated disease. Brensocatib is an oral, small-molecule, reversible DPP1 inhibitor that works by blocking DPP1, thereby reducing the activation of neutrophil serine proteases—key contributors to inflammation and tissue damage in chronic lung conditions like bronchiectasis.
-
In February 2025, The FDA granted priority review to brensocatib, an investigational treatment for patients with non-cystic fibrosis bronchiectasis. Following acceptance of the new drug application, the target action date has been set for August 12, 2025. If approved, brensocatib would become the first and only authorized therapy for bronchiectasis and the first drug in the new dipeptidyl peptidase 1 class for treating neutrophil-mediated diseases.
-
In February 2025, Verona Pharma is a biopharmaceutical company dedicated to developing and bringing to market innovative treatments for chronic respiratory diseases with considerable unmet medical needs. Ohtuvayre™ (ensifentrine) is the company’s inaugural commercial product and represents the first inhaled therapy for COPD maintenance that uniquely combines bronchodilator and non-steroidal anti-inflammatory effects in a single molecule. Ensifentrine also shows potential for treating non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory conditions.
-
In December 2024, Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a biotech firm focused on developing high-purity, pathogen-specific bacteriophage therapies for chronic pulmonary diseases and antibiotic-resistant infections, has reported encouraging topline results from its Phase 2 (“Tailwind”) trial. The study assesses AP-PA02, a novel inhaled multi-phage therapy aimed at treating chronic Pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis (NCFB).
-
In July 2024, Armata Pharmaceuticals has announced the completion of patient enrollment for its Phase II Tailwind clinical trial, which is assessing the efficacy of inhaled AP-PA02 in individuals with non-cystic fibrosis bronchiectasis (NCFB) and chronic Pseudomonas aeruginosa infection.
-
In May 2024, Insmed Incorporated announced encouraging topline results from the ASPEN study, a global Phase III randomized, double-blind, placebo-controlled trial assessing the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.
-
In April 2024, 30 Technology announced that the European Medicines Agency (EMA) has authorized the Phase I/IIa NOPA study to evaluate the safety, tolerability, and effectiveness of nebulized Nitric Oxide Formulations in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) who have Pseudomonas aeruginosa or other potentially pathogenic microorganisms (PPMs).
Non-Cystic Fibrosis Bronchiectasis Overview
Non-Cystic Fibrosis Bronchiectasis is a chronic lung condition where the airways (bronchi) become permanently widened and damaged, leading to mucus buildup, inflammation, and recurrent infections. Unlike cystic fibrosis-related bronchiectasis, this form occurs due to other causes such as previous lung infections, immune disorders, or autoimmune diseases. Common symptoms include persistent cough, excessive sputum production, breathlessness, and frequent respiratory infections. Treatment focuses on airway clearance, antibiotics for infections, and managing underlying conditions to improve lung function and quality of life.
Get a Free Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
Emerging Non-Cystic Fibrosis Bronchiectasis Drugs Under Different Phases of Clinical Development Include:
-
NP339: NovaBiotics Ltd
-
Research Programme:NCFB: Synspira Therapeutics
-
Research programme: mucolytic agents: Parion Sciences
-
CHF 6333: Chiesi Farmaceutic
-
CSL787: CSL Behring
-
HSK31858: Haisco Pharmaceutical
-
S-1226: SolAeroMed Inc.
-
Benralizumab: AstraZeneca
-
Colistimethate sodium: Zambon SpA
-
BI 1291583: Boehringer Ingelheim
-
AP-PA02: Armata Pharmaceuticals
-
ARINA-1: Renovion
Non-Cystic Fibrosis Bronchiectasis Route of Administration
Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Non-Cystic Fibrosis Bronchiectasis Molecule Type
Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types, such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics Assessment
-
Non-Cystic Fibrosis Bronchiectasis Assessment by Product Type
-
Non-Cystic Fibrosis Bronchiectasis By Stage and Product Type
-
Non-Cystic Fibrosis Bronchiectasis Assessment by Route of Administration
-
Non-Cystic Fibrosis Bronchiectasis By Stage and Route of Administration
-
Non-Cystic Fibrosis Bronchiectasis Assessment by Molecule Type
-
Non-Cystic Fibrosis Bronchiectasis by Stage and Molecule Type
DelveInsight’s Non-Cystic Fibrosis Bronchiectasis Report covers around 15+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Non-Cystic Fibrosis Bronchiectasis product details are provided in the report. Download the Non-Cystic Fibrosis Bronchiectasis pipeline report to learn more about the emerging Non-Cystic Fibrosis Bronchiectasis therapies
Some of the key companies in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market include:
Key companies developing therapies for Non-Cystic Fibrosis Bronchiectasis are – Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Haisco Pharmaceutical, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, and others.
Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis:
The Non-Cystic Fibrosis Bronchiectasis pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment.
-
Non-Cystic Fibrosis Bronchiectasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Non-Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis drugs and therapies
Non-Cystic Fibrosis Bronchiectasis Pipeline Market Drivers
Non-Cystic Fibrosis Bronchiectasis Pipeline Market Barriers
Scope of Non-Cystic Fibrosis Bronchiectasis Pipeline Drug Insight
-
Coverage: Global
-
Key Non-Cystic Fibrosis Bronchiectasis Companies: NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others
-
Key Non-Cystic Fibrosis Bronchiectasis Therapies: NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others
-
Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging therapies
-
Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market barriers
Request for Sample PDF Report for Non-Cystic Fibrosis Bronchiectasis Pipeline Assessment and clinical trials
Table of Contents
1. Non-Cystic Fibrosis Bronchiectasis Report Introduction
2. Non-Cystic Fibrosis Bronchiectasis Executive Summary
3. Non-Cystic Fibrosis Bronchiectasis Overview
4. Non-Cystic Fibrosis Bronchiectasis- Analytical Perspective In-depth Commercial Assessment
5. Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics
6. Non-Cystic Fibrosis Bronchiectasis Late Stage Products (Phase II/III)
7. Non-Cystic Fibrosis Bronchiectasis Mid Stage Products (Phase II)
8. Non-Cystic Fibrosis Bronchiectasis Early Stage Products (Phase I)
9. Non-Cystic Fibrosis Bronchiectasis Preclinical Stage Products
10. Non-Cystic Fibrosis Bronchiectasis Therapeutics Assessment
11. Non-Cystic Fibrosis Bronchiectasis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Non-Cystic Fibrosis Bronchiectasis Key Companies
14. Non-Cystic Fibrosis Bronchiectasis Key Products
15. Non-Cystic Fibrosis Bronchiectasis Unmet Needs
16 . Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers
17. Non-Cystic Fibrosis Bronchiectasis Future Perspectives and Conclusion
18. Non-Cystic Fibrosis Bronchiectasis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Non-Cystic Fibrosis Bronchiectasis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring
